Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/6/2017
SIETES contiene 91846 citas

 
 
 1 a 20 de 44 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
2.Tiene citas relacionadas Cita con resumen
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif J-C, Tendera M, Tavazzi L, Bhatt DL, Steg PG, CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;388:2142-52. [Ref.ID 100862]
3.Tiene citas relacionadas Cita con resumen
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]
4. Cita con resumen
Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL, BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015;373:610-20. [Ref.ID 99495]
5.Tiene citas relacionadas Cita con resumen
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong M-K, Kim B-K, Jang Y, Kim H-S, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371-82. [Ref.ID 99292]
6.Tiene citas relacionadas Cita con resumen
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. [Ref.ID 99086]
7.Tiene citas relacionadas Cita con resumen
Bhatt DL, Cavender MA. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?. JACC. Heart fail 2014;2:583-5. [Ref.ID 97728]
8. Cita con resumen
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto A, Botelho RV, King III SB, Negoita M, Liu M, de Paula JET, Mangione JA, Meireles GX, Castello Jr HJ, Nicolela Jr EL, Perin MA, Devito FS, Labrunie A, Salvadori Jr D, Gusmao M, Staico R, Costa Jr JR, de Castro JP, Abizaid AS, Bhatt DL, for the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22. [Ref.ID 96672]
9.Tiene citas relacionadas Cita con resumen
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. [Ref.ID 96671]
10.Tiene citas relacionadas Cita con resumen
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. [Ref.ID 96330]
11.Tiene citas relacionadas
Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. Lancet 2013;382:633-43. [Ref.ID 96027]
12.Tiene citas relacionadas
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran DJ, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzylio W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;382:605-13. [Ref.ID 96025]
13.Tiene citas relacionadas
Bhatt DL, Harrington RA, for the CHAMPION PHOENIX Executive Committee and Investigators. Platelet inhibition with cangrelor during PCI. The authors reply. N Engl J Med 2013;369:393-4. [Ref.ID 95884]
14.Tiene citas relacionadas
Bhatt DL. Timely for PCI for STEMI - Still the treatment of choice. N Engl J Med 2013;368:1446-7. [Ref.ID 95269]
15.Tiene citas relacionadas Cita con resumen
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg G, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13. [Ref.ID 95246]
16. Cita con resumen
Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL, for the REACH Registry Investigators. ß-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9. [Ref.ID 93831]
17.Tiene citas relacionadas
18. Cita con resumen
Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM, for the ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19. [Ref.ID 92103]
19.Tiene citas relacionadas Cita con resumen
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L, for the APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708. [Ref.ID 91101]
20.Tiene citas relacionadas
Bhatt DL. Evaluation of agents to reduce infarct size. It can be quite REVEALing. JAMA 2011;305:1908-9. [Ref.ID 90797]
Seleccionar todas
 
 1 a 20 de 44 siguiente >>